Current Treatment Strategies for EGFR-Mutated Non-Small Cell Lung Cancer: From First Line to Beyond Osimertinib Resistance

The authors describe current pharmacotherapeutic strategies for epidermal growth factor receptor (EGFR)-mutated NSCLC based on the results of clinical trials and the latest published data.